Skip Navigation LinksHome > April 2014 - Volume 20 - Issue 2, Cerebrovascular Disease > Evaluation and Management of Acute Ischemic Stroke
CONTINUUM: Lifelong Learning in Neurology:
doi: 10.1212/01.CON.0000446101.44302.47
Review Articles

Evaluation and Management of Acute Ischemic Stroke

Khatri, Pooja MD, MSc

Collapse Box

Abstract

Purpose of Review:

This review provides an overview of emergent evaluation of the stroke patient with an emphasis on practical issues regarding ischemic stroke treatment.

Recent Findings:

The IV recombinant tissue-type plasminogen activator (rtPA) treatment window has been expanded from 3 to 4.5 hours from symptom onset. The evidence for better outcomes with more rapid initiation of reperfusion therapies is very strong. Adjunctive endovascular therapy has not been shown to benefit all patients with moderate or severe strokes, and investigations are underway to identify subgroups that may benefit from this approach. Endovascular therapy should be considered for patients who are ineligible for IV rtPA and can begin treatment within 6 hours of stroke onset.

Summary:

Effective emergent evaluation of a stroke patient requires well-organized systems that maximize speed of assessment and administration of appropriate therapies, including IV rtPA and endovascular therapies.

Copyright © 2014 by the American Academy of Neurology.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login